Immune Regulation’s first-in-class candidates reset the immune system allowing restoration of control over pathogenic and inflammatory immune cells.

Immune Regulation’s first-in-class candidates reset the immune system allowing restoration of control over pathogenic and inflammatory immune cells.

IRL201805 (‘1805)

‘1805 is a first-in-class compound derived from the endogenous immuno-regulatory protein (Binding Immunoglobulin Protein, BiP). ‘1805 has demonstrated long duration of activity and disease remission with a good tolerability profile in a phase 1/2A study in patients with rheumatoid arthritis who have failed previous therapies.

Read More

IRL201104 (‘1104)

‘1104 is a first-in-class compound derived from the endogenous immuno-regulatory protein (mTB chaperonin 60.1). ‘1104 uniquely reduces three key cells involved in both allergic and non-allergic inflammation: eosinophils, neutrophils and lymphocytes.

Read More